Powered by: Motilal Oswal
2025-02-12 01:53:26 pm | Source: Accord Fintech
Marksans Pharma gains on reporting 27% rise in Q3 consolidated net profit
Marksans Pharma gains on reporting 27% rise in Q3 consolidated net profit

Marksans Pharma is currently trading at Rs 252.55, up by 1.10 points or 0.44% from its previous closing of Rs 251.45 on the BSE.

The scrip opened at Rs 252.05 and has touched a high and low of Rs 255.15 and Rs 239.25 respectively. So far 143344 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 358.50 on 05-Dec-2024 and a 52-week low of Rs 126.05 on 14-Mar-2024.

Last one week high and low of the scrip stood at Rs 276.15 and Rs 239.25 respectively. The current market cap of the company is Rs 11290.57 crore.

The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 26.26% and 29.87% respectively.

The company has reported over two-fold jump in its net profit at Rs 55.46 crore for Q3FY25 as compared to Rs 25.29 crore for the same quarter in the previous year. Total income of the company increased by 37.78% at Rs 334.37 crore for Q3FY25 as compared to Rs 242.69 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 26.64% rise in its net profit at Rs 105.07 crore for the quarter ended December 31, 2024 as compared to Rs 82.97 crore for the same quarter in the previous year. Total income of the company increased by 20.10% at Rs 709.70 crore for Q3FY25 as compared to Rs 590.93 crore for the corresponding quarter previous year.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here